Author

Roshen Alharthi

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alan D. D’AndreaiD· 1 shared Astrid ZimmermanniD· 1 shared Bose S. KochupurakkaliD· 1 shared Geoffrey Ira ShapiroiD· 1 shared Gregory Michael CoteiD· 1 shared Ian A. RoundtreeiD· 1 shared Jie HaoiD· 1 shared Joachim AlbersiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan D. D’AndreaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy

Timothy B. Branigan, Roshen Alharthi, Bose S. Kochupurakkal, Jie Hao, Steffie Revia, Joachim Albers, Mu-Yan Cai, Yuqing Jiao, Kelsey McQueen, Sirisha Mukkavalli, Ian A. Roundtree, Gregory Michael Cote, Prafulla C. Gokhale, Kalindi Parmar, Alan D. D’Andrea, , Geoffrey Ira Shapiro

This study shows DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells, reducing ATR inhibitor efficacy, and suggests combining ATR and DNA-PK inhibition could enhance treatment in such cancers.

bioRxiv · Oct 28, 2026 · PreprintCancer Biology